Clovis Updates Data from Prostate, Ovarian Cancer Trials at ESMO

43.9% conrmed objective response rate (ORR) in 57 RECIST * -evaluable patients with metastatic castration- resistant prostate cancer (mCRPC) and a BRCA1/2 mutation

52.0% conrmed prostate-specic antigen (PSA) response in 98 PSA-evaluable patients with mCRPC and a BRCA1/2 mutation

The safety pro le of Rubraca was consistent with prior reports from TRITON2 and for those patients with ovarian cancer and other solid tumors

Supplemental new drug application (NDA) for Rubraca in BRCA1/2-mutant advanced prostate cancer on track for Q4 2019

Clovis Oncology also highlights eCcacy and safety of Rubraca in recurrent ovarian cancer

https://www.marketscreener.com/CLOVIS-ONCOLOGY-INC-9500801/news/Clovis-Oncology-Download-PDF-format-download-opens-in-new-window-29274509/